Fibromyalgia, chronic pain
Conditions
Interventions
None listed
Sponsors
Department of Psychosomatic Medicine, Graduate School of Medical Sciences, Kyushu University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: [Fibromyalgia] (1) Patients diagnosed with fibromyalgia. (2) Patients who fully understand this research plan and can give their consent. (3) Patients who are at least 18 years of age at the time consent is obtained. [Chronic pain] (1) Patients who have pain that lasts more than 3 months but do not meet the diagnostic criteria for fibromyalgia. (2) Patients who fully understand this research plan and can give their consent. (3) Patients who are at least 18 years of age at the time consent is obtained. [Healthy control] (1) Healthy subjects who do not have pain lasting more than 3 months. (2) Persons who fully understand this research plan and can give their consent. (3) Persons who are at least 18 years of age at the time consent is obtained.
Exclusion criteria
Exclusion criteria: [Fibromyalgia] (1) Patients with symptoms of anemia (hemoglobin 8 g/dl or less) (2) Patients with poor general condition (PS value >3) (3) Patients diagnosed with autoimmune disease, chronic infectious disease, demyelinating disease, complement-related disease (PNH, NMO, MS), malignant disease (4) Other patients deemed by the investigator to be inappropriate as research subjects. [Chronic pain] (1) Patients with symptoms of anemia (hemoglobin of 8 g/dl or less) (2) Patients with poor general condition (numerical value: PS value 3 or higher) (3) Those diagnosed with autoimmune disease, chronic infectious disease, demyelinating disease, complement-related disease (PNH, NMO, MS), or malignant disease (4) Other subjects deemed by the investigator to be inappropriate as research subjects. [Healthy control] (1) Those with symptoms of anemia (hemoglobin 8 g/dl or less) (2) Patients with poor general condition (PS value of 3 or higher) (3) Patients receiving treatment for pain (4) Those diagnosed with autoimmune disease, chronic infectious disease, demyelinating disease, complement-related disease (PNH, NMO, MS), or malignant disease (5) Any other person whom the investigator deems inappropriate as a research subject.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Concentration of complement (C3a, C5a, sC5b-9) in peripheral blood. | — |
Secondary
| Measure | Time frame |
|---|---|
| The relationship between the concentration of complement and clinical features such as psychological and physiological measurements. | — |
Countries
Japan
Contacts
Public ContactKoji FUJIMOTO
Kyushu University Department of Psychosomatic Medicine, Graduate School of Medical Sciences.
Outcome results
None listed